- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05386953
Administration peropératoire de solution saline normale et lésions rénales aiguës chez les patients subissant une transplantation hépatique
Administration peropératoire de solution saline normale et lésions rénales aiguës chez les patients subissant une transplantation hépatique : une étude de cohorte rétrospective
The investigators attempted to investigate the association of the type of crystalloid administered during liver transplantation with postoperative clinical outcomes. The investigators hypothesized that the greater amount of normal saline or half-saline administered during liver transplantation might be associated with the increased risk of acute kidney injury compared to the balanced crystalloids.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Liver transplantation requires a long operation time and is often associated with a significant amount of surgical bleeding. It is common for the anesthesiologist to infuse large amounts of fluid or blood products due to bleeding, hemodynamic instability, or ascites drainage. Therefore, in the anesthesia for liver transplantation, optimal management of fluid administration is necessary and the choice of the type of crystalloid may affect the prognosis or the incidence of postoperative complications of patients.
The investigators attempted to investigate the association of the type of crystalloid administered during liver transplantation with postoperative clinical outcomes. The investigators hypothesized that the greater amount of normal saline or half-saline administered during liver transplantation might be associated with the increased risk of acute kidney injury compared to the balanced crystalloids.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Seoul, Corée du Sud, 03080
- Seoul National University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients received liver transplantation surgery in a single tertiary care university hospital
La description
Inclusion Criteria:
- Consecutive patients who underwent living or deceased donor liver transplantation at our tertiary care university hospital between 2004 and 2018
Exclusion Criteria:
- patients with baseline renal dysfunction of hepatorenal syndrome or chronic kidney disease
- missing preoperative serum creatinine value
- missing other baseline or outcome variables
- patients who received retransplantation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: RETROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Balanced group
Patients who received balanced crystalloids of lactated Ringer's solution or plasma solution during liver transplantation surgery |
Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
Autres noms:
|
|
Saline group
Patients who received only normal saline during liver transplantation surgery |
Patients received normal saline as a maintenance crystalloid during liver transplantation surgery. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Acute kidney injury
Délai: the first 7 postoperative days
|
The investigators defined acute kidney injury by the KDIGO (Kidney Disease Improving Global Outcomes) criteria, which was determined according to the greatest change in serum creatinine level during the postoperative seven days (Stage 1: more than 1.5-fold; stage 2: more than 2-fold; stage 3: more than 3-fold increase of baseline or increase in SCr to ≥ 4.0 mg/dL or the initiation of renal replacement therapy). The most recent SCr level measured before surgery was collected as a baseline value. |
the first 7 postoperative days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of postoperative hemodialysis
Délai: the first month after admission
|
the incidence of new-onset postoperative hemodialysis during hospitalization |
the first month after admission
|
|
Early allograft dysfunction
Délai: the first 7 postoperative days
|
One or more of the following are present within the first 7 postoperative days: total bilirubin ≥ 10 mg/dL, PT (prothrombin time):INR (international normalized ratio)≥ 1.6, or AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 2000 IU/L |
the first 7 postoperative days
|
|
In-hospital mortality
Délai: the first month after admission
|
all-cause mortality during hospitalization |
the first month after admission
|
|
One-year mortality
Délai: one year after transplantation
|
all-cause mortality during one year after transplantation |
one year after transplantation
|
|
Length of intensive care unit stay
Délai: the first month after admission
|
Length of intensive care unit stay after transplantation |
the first month after admission
|
|
Length of hospital stay
Délai: the first month after admission
|
Length of hospital stay after transplantation |
the first month after admission
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Won Ho Kim, MD, PhD, Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladies du système digestif
- Maladies du foie
- Insuffisance hépatique
- Insuffisance hépatique
- Fibrose
- Conditions pathologiques, signes et symptômes
- La cirrhose du foie
- Maladie hépatique en phase terminale
- Préparations pharmaceutiques
- Solutions cristalloïdes
- Solutions isotoniques
- Solutions
- Solution saline
- Lactate de la sonnerie
- stable plasma protein solution
Autres numéros d'identification d'étude
- H-2108-173-1248
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .